Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Utility of the RIG-I agonist triphosphate RNA for melanoma therapy.

Helms MW, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann C, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar TR, Schnurr MM, Endres S, Wiederschain D, Scheidler S, Rothenfußer S, Brunner B, König LM.

Mol Cancer Ther. 2019 Sep 12. pii: molcanther.1262.2018. doi: 10.1158/1535-7163.MCT-18-1262. [Epub ahead of print]

PMID:
31515294
2.

Ischemic Postconditioning (IPostC) Protects Fibrotic and Cirrhotic Rat Livers after Warm Ischemia.

Schewe J, Makeschin MC, Liss I, Mayr D, Zhang J, Khandoga A, Rothenfußer S, Schnurr M, Gerbes AL, Steib CJ.

Can J Gastroenterol Hepatol. 2019 Jun 9;2019:5683479. doi: 10.1155/2019/5683479. eCollection 2019.

3.

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.

Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J.

Hepatology. 2019 Jan;69(1):376-393. doi: 10.1002/hep.30190. Epub 2018 Dec 22.

4.

Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.

Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt KAM, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S, Kobold S.

Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12994-12999. doi: 10.1073/pnas.1705165114. Epub 2017 Nov 17.

5.

Th17 micro-milieu regulates NLRP1-dependent caspase-5 activity in skin autoinflammation.

Zwicker S, Hattinger E, Bureik D, Batycka-Baran A, Schmidt A, Gerber PA, Rothenfusser S, Gilliet M, Ruzicka T, Wolf R.

PLoS One. 2017 Apr 19;12(4):e0175153. doi: 10.1371/journal.pone.0175153. eCollection 2017.

6.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

Oncoimmunology. 2016 May 31;5(7):e1189051. doi: 10.1080/2162402X.2016.1189051. eCollection 2016 Jul.

7.

The E3 Ubiquitin Ligase TRIM9 Is a Filopodia Off Switch Required for Netrin-Dependent Axon Guidance.

Menon S, Boyer NP, Winkle CC, McClain LM, Hanlin CC, Pandey D, Rothenfußer S, Taylor AM, Gupton SL.

Dev Cell. 2015 Dec 21;35(6):698-712. doi: 10.1016/j.devcel.2015.11.022.

8.

Immunotherapy in Tumors.

Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.

Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review.

9.

In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.

Senft D, Weber A, Saathoff F, Berking C, Heppt MV, Kammerbauer C, Rothenfusser S, Kellner S, Kurgyis Z, Besch R, Häcker G.

Cell Death Dis. 2015 Nov 26;6:e1996. doi: 10.1038/cddis.2015.341.

10.

Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.

Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C.

Cancer Res. 2015 Nov 1;75(21):4483-93. doi: 10.1158/0008-5472.CAN-14-3499. Epub 2015 Oct 2.

11.

Reply.

Hoffmann F, Endres S, Rothenfusser S.

Hepatology. 2016 Mar;63(3):1062-3. doi: 10.1002/hep.27955. Epub 2015 Jul 23. No abstract available.

PMID:
26106015
12.

Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.

Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger JC, Schnurr M, Endres S, Rothenfußer S.

J Natl Cancer Inst. 2015 Jun 23;107(8). pii: djv146. doi: 10.1093/jnci/djv146. Print 2015 Aug.

13.

Strategies to relieve immunosuppression in pancreatic cancer.

Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S.

Immunotherapy. 2015;7(4):363-76. doi: 10.2217/imt.15.9. Review.

PMID:
25917628
14.

Cellular Uptake of Tile-Assembled DNA Nanotubes.

Kocabey S, Meinl H, MacPherson IS, Cassinelli V, Manetto A, Rothenfusser S, Liedl T, Lichtenegger FS.

Nanomaterials (Basel). 2014 Dec 30;5(1):47-60. doi: 10.3390/nano5010047.

15.

Modes of action of TLR7 agonists in cancer therapy.

Kobold S, Wiedemann G, Rothenfußer S, Endres S.

Immunotherapy. 2014;6(10):1085-95. doi: 10.2217/imt.14.75. Review.

PMID:
25428647
16.

Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.

J Natl Cancer Inst. 2014 Nov 24;107(1):364. doi: 10.1093/jnci/dju364. Print 2015 Jan.

PMID:
25424197
17.

Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus.

Hoffmann FS, Schmidt A, Dittmann Chevillotte M, Wisskirchen C, Hellmuth J, Willms S, Gilmore RH, Glas J, Folwaczny M, Müller T, Berg T, Spengler U, Fitzmaurice K, Kelleher D, Reisch N, Rice CM, Endres S, Rothenfusser S.

Hepatology. 2015 Feb;61(2):460-70. doi: 10.1002/hep.27344. Epub 2015 Jan 5.

18.

Isolation of RIG-I-associated RNAs from virus-infected cells.

Schmidt A, Linder A, Linder N, Rothenfusser S.

Methods Mol Biol. 2014;1169:37-44. doi: 10.1007/978-1-4939-0882-0_4.

PMID:
24957227
19.

A semi-automated method for isolating functionally intact mitochondria from cultured cells and tissue biopsies.

Schmitt S, Saathoff F, Meissner L, Schropp EM, Lichtmannegger J, Schulz S, Eberhagen C, Borchard S, Aichler M, Adamski J, Plesnila N, Rothenfusser S, Kroemer G, Zischka H.

Anal Biochem. 2013 Dec 1;443(1):66-74. doi: 10.1016/j.ab.2013.08.007. Epub 2013 Aug 19.

PMID:
23969012
20.

The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.

Hohenauer T, Berking C, Schmidt A, Haferkamp S, Senft D, Kammerbauer C, Fraschka S, Graf SA, Irmler M, Beckers J, Flaig M, Aigner A, Höbel S, Hoffmann F, Hermeking H, Rothenfusser S, Endres S, Ruzicka T, Besch R.

EMBO Mol Med. 2013 Jun;5(6):919-34. doi: 10.1002/emmm.201201862. Epub 2013 May 13.

21.

Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling proteins independently of AIM2 and RNA polymerase III.

Wenzel M, Wunderlich M, Besch R, Poeck H, Willms S, Schwantes A, Kremer M, Sutter G, Endres S, Schmidt A, Rothenfusser S.

J Immunol. 2012 Jan 1;188(1):394-403. doi: 10.4049/jimmunol.1100523. Epub 2011 Dec 2.

22.

Sensing of viral nucleic acids by RIG-I: from translocation to translation.

Schmidt A, Rothenfusser S, Hopfner KP.

Eur J Cell Biol. 2012 Jan;91(1):78-85. doi: 10.1016/j.ejcb.2011.01.015. Epub 2011 Apr 14. Review.

23.

Pattern recognition of viral nucleic acids by RIG-I-like helicases.

Schmidt A, Endres S, Rothenfusser S.

J Mol Med (Berl). 2011 Jan;89(1):5-12. doi: 10.1007/s00109-010-0672-8. Epub 2010 Sep 4. Review.

PMID:
20820752
24.

Immunostimulatory RNA blocks suppression by regulatory T cells.

Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, Sparwasser T, Besch R, Poeck H, Hornung V, Hartmann G, Rothenfusser S, Bourquin C, Endres S.

J Immunol. 2010 Jan 15;184(2):939-46. doi: 10.4049/jimmunol.0901245. Epub 2009 Dec 4.

25.

Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.

Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.

Nat Immunol. 2010 Jan;11(1):63-9. doi: 10.1038/ni.1824. Epub 2009 Nov 15. Erratum in: Nat Immunol. 2014 Jan;15(1):109.

PMID:
19915568
26.

Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, Hornung V, Endres S, Ruzicka T, Rothenfusser S, Hartmann G.

J Clin Invest. 2009 Aug;119(8):2399-411. doi: 10.1172/JCI37155. Epub 2009 Jul 20.

27.

5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I.

Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, Wenzel M, Hoffmann FS, Michallet MC, Besch R, Hopfner KP, Endres S, Rothenfusser S.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12067-72. doi: 10.1073/pnas.0900971106. Epub 2009 Jul 2.

28.

Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes.

Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S, Bourquin C, Goutagny N, Jiang Z, Fitzgerald KA, Rothenfusser S, Endres S, Hartmann G, Hornung V.

J Immunol. 2009 Jun 1;182(11):6824-33. doi: 10.4049/jimmunol.0803001.

29.

The regulatory domain of the RIG-I family ATPase LGP2 senses double-stranded RNA.

Pippig DA, Hellmuth JC, Cui S, Kirchhofer A, Lammens K, Lammens A, Schmidt A, Rothenfusser S, Hopfner KP.

Nucleic Acids Res. 2009 Apr;37(6):2014-25. doi: 10.1093/nar/gkp059. Epub 2009 Feb 10.

30.

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.

Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Häcker G, Neuenhahn M, Busch D, Ruland J, Rothenfusser S, Prinz M, Hornung V, Endres S, Tüting T, Hartmann G.

Nat Med. 2008 Nov;14(11):1256-63. doi: 10.1038/nm.1887. Epub 2008 Nov 2.

PMID:
18978796
31.

Toll-like receptor stimulation induces higher TNF-alpha secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome.

Yeganeh M, Henneke P, Rezaei N, Ehl S, Thiel D, Matamoros N, Pietrogrande C, Espanol T, Litzman J, Franco JL, Sanal O, Kilic SS, Breborowicz A, Plebani A, Renner E, Rothenfusser S, Hawn TR, Woellner C, Grimbacher B.

Int Arch Allergy Immunol. 2008;146(3):190-4. doi: 10.1159/000115886. Epub 2008 Feb 11.

PMID:
18268386
32.

P2Y receptor signaling regulates phenotype and IFN-alpha secretion of human plasmacytoid dendritic cells.

Shin A, Toy T, Rothenfusser S, Robson N, Vorac J, Dauer M, Stuplich M, Endres S, Cebon J, Maraskovsky E, Schnurr M.

Blood. 2008 Mar 15;111(6):3062-9. Epub 2007 Nov 9.

33.

Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium.

Hartmann E, Graefe H, Hopert A, Pries R, Rothenfusser S, Poeck H, Mack B, Endres S, Hartmann G, Wollenberg B.

Clin Vaccine Immunol. 2006 Nov;13(11):1278-86. Epub 2006 Aug 23.

34.

The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I.

Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A, Yamamoto M, Akira S, Fitzgerald KA.

J Immunol. 2005 Oct 15;175(8):5260-8.

35.

No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome.

Renner ED, Pawlita I, Hoffmann F, Hornung V, Hartl D, Albert M, Jansson A, Endres S, Hartmann G, Belohradsky BH, Rothenfusser S.

J Clin Immunol. 2005 Jul;25(4):321-8.

PMID:
16133988
36.

CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.

Marschner A, Rothenfusser S, Hornung V, Prell D, Krug A, Kerkmann M, Wellisch D, Poeck H, Greinacher A, Giese T, Endres S, Hartmann G.

Eur J Immunol. 2005 Aug;35(8):2347-57.

37.

Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells.

Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, Johnson J, Englert S, Ketterer T, Heckl W, Thalhammer S, Endres S, Hartmann G.

J Biol Chem. 2005 Mar 4;280(9):8086-93. Epub 2004 Dec 8.

38.

Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus.

Hornung V, Schlender J, Guenthner-Biller M, Rothenfusser S, Endres S, Conzelmann KK, Hartmann G.

J Immunol. 2004 Nov 15;173(10):5935-43.

39.

Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help.

Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, Jahrsdorfer B, Giese T, Endres S, Hartmann G.

Blood. 2004 Apr 15;103(8):3058-64. Epub 2003 Dec 30.

40.

IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.

Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, Tuma E, Giese T, Ellwart JW, Endres S, Hartmann G.

J Immunol. 2004 Jan 15;172(2):954-63.

41.

CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S, Hartmann G.

Blood. 2004 Mar 15;103(6):2162-9. Epub 2003 Nov 20.

42.

Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.

Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G.

Cancer Res. 2003 Oct 1;63(19):6478-87.

43.

Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells.

Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J, Davis ID, Cebon J, Maraskovsky E.

Blood. 2004 Feb 15;103(4):1391-7. Epub 2003 Oct 9.

44.

Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.

Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S.

Eur J Immunol. 2003 Jun;33(6):1633-41.

45.

Recent advances in immunostimulatory CpG oligonucleotides.

Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G.

Curr Opin Mol Ther. 2003 Apr;5(2):98-106. Review.

PMID:
12772497
46.

[Hepatitis of unknown origin with protracted liver failure in a 48-year-old patient with significantly increased pANCA titer].

Sohn HY, Krötz F, Rothenfusser S, Zachoval R, Siegert S, Löhrs U, Heldwein W.

Internist (Berl). 2003 Mar;44(3):354-8. German.

PMID:
12731422
47.

Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.

Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G.

J Immunol. 2003 May 1;170(9):4465-74.

48.

Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.

Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A.

J Immunol. 2003 Apr 15;170(8):4069-76.

49.

CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.

Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G.

J Immunol. 2003 Apr 1;170(7):3468-77.

50.

Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.

Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G.

Eur J Immunol. 2002 Nov;32(11):3235-45.

Supplemental Content

Loading ...
Support Center